Roche obtains Spark Therapeutics

Following on from the regulatory approval by all government authorities, Roche have officially announced the attainment of Spark Therapeutics (ST), which will allow the companies to innovate gene therapies and revolutionaries the future in medicine. Despite working within the Roche Group, ST will still function as an independent company.

CEO of Roche, Severin Schwan, stated: “We are excited about this important milestone because we believe that together Roche and Spark will be able to significantly improve the lives of patients through innovative gene therapies. This acquisition supports our long lasting commitment to bringing transformational therapies and innovative approaches to people around the world with serious diseases.”

CEO and Co-founder of Spark Therapeutics, Jeffrey D. Marrazzo, stated: “Today ushers in a new and promising era in the development of genetic medicines for patients and families living with inherited diseases and beyond. Spark and Roche share an ethos of imagining the unimaginable. Together we have the potential to change the future of medicine and deliver the medicines of tomorrow today. We couldn’t be more thrilled about what’s next.”